Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11046142
Rodriguez MS, et al. (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20, 8458-67 11046142
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

K370-ub - p53 (human)
Modsite: RAHsSHLkskkGQst SwissProt Entrez-Gene
Orthologous residues
p53 (human): K370‑ub, p53 iso2 (human): , p53 iso4 (human): K331‑ub, p53 (mouse): K367‑ub, p53 iso2 (mouse): , p53 (rat): K368‑ub, p53 (rabbit): K368‑ub, p53 (green monkey): K370‑ub
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  multiple sites mutants have been used
Enzymes shown to modify site in vitro
Type Enzyme
UBIQUITIN LIGASE MDM2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MG132 decrease
Downstream Regulation
Effect of modification (function):  protein degradation
Effect of modification (process):  transcription, inhibited
Comments:  K370/372/373/381/382/386/R mutant shows 613-fold activation of p53

K372-ub - p53 (human)
Modsite: HsSHLkskkGQstsR SwissProt Entrez-Gene
Orthologous residues
p53 (human): K372‑ub, p53 iso2 (human): , p53 iso4 (human): K333‑ub, p53 (mouse): K369‑ub, p53 iso2 (mouse): , p53 (rat): K370‑ub, p53 (rabbit): K370‑ub, p53 (green monkey): K372‑ub
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  multiple sites mutants have been used
Enzymes shown to modify site in vitro
Type Enzyme
UBIQUITIN LIGASE MDM2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MG132 decrease
Downstream Regulation
Effect of modification (function):  protein degradation
Effect of modification (process):  transcription, inhibited
Comments:  K370/372/373/381/382/386/R mutant shows 613-fold activation of p53

K373-ub - p53 (human)
Modsite: sSHLkskkGQstsRH SwissProt Entrez-Gene
Orthologous residues
p53 (human): K373‑ub, p53 iso2 (human): , p53 iso4 (human): K334‑ub, p53 (mouse): K370‑ub, p53 iso2 (mouse): , p53 (rat): K371‑ub, p53 (rabbit): K371‑ub, p53 (green monkey): K373‑ub
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  multiple sites mutants have been used
Enzymes shown to modify site in vitro
Type Enzyme
UBIQUITIN LIGASE MDM2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MG132 decrease
Downstream Regulation
Effect of modification (function):  protein degradation
Effect of modification (process):  transcription, inhibited
Comments:  K370/372/373/381/382/386/R mutant shows 613-fold activation of p53

K381-ub - p53 (human)
Modsite: GQstsRHkkLMFktE SwissProt Entrez-Gene
Orthologous residues
p53 (human): K381‑ub, p53 iso2 (human): , p53 iso4 (human): K342‑ub, p53 (mouse): K378‑ub, p53 iso2 (mouse): , p53 (rat): K379‑ub, p53 (rabbit): K379‑ub, p53 (green monkey): K381‑ub
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  multiple sites mutants have been used
Enzymes shown to modify site in vitro
Type Enzyme
UBIQUITIN LIGASE MDM2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MG132 decrease
Downstream Regulation
Effect of modification (function):  protein degradation
Effect of modification (process):  transcription, inhibited
Comments:  K370/372/373/381/382/386/R mutant shows 613-fold activation of p53

K382-ub - p53 (human)
Modsite: QstsRHkkLMFktEG SwissProt Entrez-Gene
Orthologous residues
p53 (human): K382‑ub, p53 iso2 (human): , p53 iso4 (human): K343‑ub, p53 (mouse): K379‑ub, p53 iso2 (mouse): , p53 (rat): K380‑ub, p53 (rabbit): K380‑ub, p53 (green monkey): K382‑ub
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  multiple sites mutants have been used
Enzymes shown to modify site in vitro
Type Enzyme
UBIQUITIN LIGASE MDM2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MG132 decrease
Downstream Regulation
Effect of modification (function):  protein degradation
Effect of modification (process):  transcription, inhibited
Comments:  K370/372/373/381/382/386/R mutant shows 613-fold activation of p53

K386-ub - p53 (human)
Modsite: RHkkLMFktEGPDsD SwissProt Entrez-Gene
Orthologous residues
p53 (human): K386‑ub, p53 iso2 (human): , p53 iso4 (human): K347‑ub, p53 (mouse): K383‑ub, p53 iso2 (mouse): , p53 (rat): K384‑ub, p53 (rabbit): K384‑ub, p53 (green monkey): K386‑ub
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  multiple sites mutants have been used
Enzymes shown to modify site in vitro
Type Enzyme
UBIQUITIN LIGASE MDM2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MG132 decrease
Downstream Regulation
Effect of modification (function):  protein degradation
Effect of modification (process):  transcription, inhibited
Comments:  K370/372/373/381/382/386/R mutant shows 613-fold activation of p53